Jersey City News Today | 2 Min News | The Daily News Now!
FDA just approved Leqembi, the first drug in years to target Alzheimer’s by clearing brain amyloid plaques—offering hope for early-stage patients, but with caveats: modest benefits, serious side effects, and a staggering $56K annual cost. The approval marks a breakthrough, yet real-world access, safety monitoring, and ongoing research will determine its true impact on the fight against this devastating disease. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/f3bae4381c5860d1
300 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Jersey City News Today | 2 Min News | The Daily News Now!!